Multiple Ascending Dose Trial of BYK324677 in Healthy Volunteers
This study has been completed.
Information provided by (Responsible Party):
First received: June 28, 2011
Last updated: May 4, 2012
Last verified: May 2012
This monocenter trial is conducted to obtain first data on safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) after multiple ascending doses of BYK324677 in humans. In addition, the trial should provide preliminary information on a possible influence of sex, food intake, and posology (once or twice daily administration of BYK324677) to support the further planning of the drug development programme.
Type 2 Diabetes Mellitus
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
||Investigation of Safety/Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Doses of BYK324677 in Healthy Volunteers. A Monocentre, Placebo-controlled, Cross-over, Double-blind, Randomised Trial
Primary Outcome Measures:
- Assessment of the safety/tolerability of multiple dosing of BYK324677 given once daily (SID) or twice daily (BID) in healthy volunteers. [ Time Frame: during screening, clinical part (treatment) and end-of-trial examination (up to 8 weeks) ]
Safety/tolerability variables: adverse events (AEs), vital signs (BP, pulse rate, body temperature), 12-lead ECG (PQ [=PR], QRS, QT, QTcF and QTcB intervals, heart rate), laboratory parameters including urinalysis.
Secondary Outcome Measures:
- Exploratory assessment of the pharmacokinetics (PK) of multiple dosing of BYK324677 (SID or BID) under steady state conditions in healthy volunteers. [ Time Frame: during Treatment Period 1 and Period 2 (up to 3 weeks) ]
Pharmacokinetic variables (e.g. AUC, Cmax, tmax, t1/2) of BYK324677 on Day 1 and Day 5 (single dose i.e. after first Investigational medicinal product (IMP) dose vs steady state) as well as on Day 4 and Day 5 (fed vs fasted, respectively).
- Exploratory assessment of the pharmacodynamics (PD) of multiple dosing of BYK324677 (SID or BID) under steady state conditions in healthy volunteers. [ Time Frame: during Treatment Period 1 and Period 2 (up to 3 weeks) ]
Pharmacodynamic variables glucose, insulin, glucagon-like peptide 1 and glucagon on Day -1, Day 4 (fed) and Day 5 (fasted).
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||September 2011 (Final data collection date for primary outcome measure)
Active Comparator: BYK324677
- Dose group I: total daily dose 2 mg (1 mg BID or 2 mg SID)
- Dose group II: total daily dose 4 mg (2 mg BID or 4 mg SID)
- Dose group III: total daily dose 6 mg (3 mg BID or 6 mg SID)
In each dose group 12 subjects (8 subjects BYK324677, 4 subjects placebo) are planned.
Within each dose group, the subjects will be randomised to either BYK324677 or placebo at a ratio of 2:1.
Within each verum group, the subjects will be randomised to one of the 2 treatment sequences (BID/SID or SID/BID, ratio 1:1) and treated in a cross-over manner.
capsules, administered orally
Placebo Comparator: Placebo
capsules, administered orally
|Ages Eligible for Study:
||18 Years to 45 Years (Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Given written informed consent
- Healthy male and female subjects. Assessed as healthy based on a screening examination including medical history, physical examination, blood pressure (systolic ≤140 mmHg, diastolic ≤90 mmHg), pulse rate (within 45-95 bpm), ECG assessment, and clinical laboratory results
- Body mass index (BMI) between ≥18 and ≤28 kg/m², and a body weight ≥60 kg
- History or current evidence of specified diseases
- History of malignancy in the past 5 years
- Gain or loss in body weight of more than 5% within the last 2 months or use of weight-loss medication within the last 3 months
- ECG abnormalities of clinical relevance
- Suspected hypersensitivity to the trial medication
- Positive virology tests indicating acute or chronic infections
- Clinically relevant laboratory parameters outside a specified range
- Use of specified medications within certain time frames or use of certain co-medications
- Abuse of alcohol or drugs
- Dietary habits that would prevent from taking standardised meals
- Female subjects: positive pregnancy test; lack of medically reliable methods of contraception during the trial
- Donation of blood
- Smoking within the last 3 months
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01386541
|Nycomed Investigational site
|Mannheim, Germany, 68167 |
History of Changes
|Other Study ID Numbers:
2010-023857-12 ( EudraCT Number )
|Study First Received:
||June 28, 2011
||May 4, 2012
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 29, 2017
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Endocrine System Diseases